Torrent Pharmaceuticals received a Form 483 with one observation from the USFDA after an inspection of its Pithampur manufacturing facility. The observation is procedural in nature and the company will respond within the prescribed timeframe.
Photograph: Yves Herman/Reuters
New Delhi, Sep 20 (PTI) Torrent Pharmaceuticals on Friday said the US health regulator has issued a Form 483 with one observation after inspecting its Pithampur-based manufacturing facility.
The US Food & Drug Administration (USFDA) conducted a routine GMP inspection of the company's formulation manufacturing plant at Pithampur, Madhya Pradesh from September 16-20, the drug maker said in a regulatory filing.
"At the end of the inspection, the agency issued a Form FDA 483 with one observation which is procedural in nature," it added.
The drug maker will respond to the USFDA within the prescribed timeframe and will work in close collaboration with it to address the observation at the earliest possible time, the company said.
As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Torrent Pharma shares were trading 2.97 per cent higher at Rs 3,450 apiece on BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback